- Home
- KALA vs CLNN Comparison
KALA vs CLNN Comparison
Compare KALA & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- CLNN
- Stock Information
- Founded
- KALA 2009
- CLNN 2012
- Country
- KALA United States
- CLNN United States
- Employees
- KALA N/A
- CLNN N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- CLNN Biotechnology: Pharmaceutical Preparations
- Sector
- KALA Health Care
- CLNN Health Care
- Exchange
- KALA Nasdaq
- CLNN Nasdaq
- Market Cap
- KALA 26.2M
- CLNN 23.1M
- IPO Year
- KALA 2017
- CLNN N/A
- Fundamental
- Price
- KALA $3.52
- CLNN $4.90
- Analyst Decision
- KALA Strong Buy
- CLNN Strong Buy
- Analyst Count
- KALA 3
- CLNN 5
- Target Price
- KALA $14.00
- CLNN $40.00
- AVG Volume (30 Days)
- KALA 55.2K
- CLNN 114.2K
- Earning Date
- KALA 05-14-2025
- CLNN 05-07-2025
- Dividend Yield
- KALA N/A
- CLNN N/A
- EPS Growth
- KALA N/A
- CLNN N/A
- EPS
- KALA N/A
- CLNN N/A
- Revenue
- KALA N/A
- CLNN $350,000.00
- Revenue This Year
- KALA N/A
- CLNN N/A
- Revenue Next Year
- KALA N/A
- CLNN $1,667.28
- P/E Ratio
- KALA N/A
- CLNN N/A
- Revenue Growth
- KALA N/A
- CLNN N/A
- 52 Week Low
- KALA $2.92
- CLNN $2.28
- 52 Week High
- KALA $11.20
- CLNN $9.20
- Technical
- Relative Strength Index (RSI)
- KALA 42.83
- CLNN 83.09
- Support Level
- KALA $3.67
- CLNN $2.28
- Resistance Level
- KALA $4.16
- CLNN $2.90
- Average True Range (ATR)
- KALA 0.31
- CLNN 0.34
- MACD
- KALA 0.05
- CLNN 0.20
- Stochastic Oscillator
- KALA 34.20
- CLNN 98.13
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.